(RTTNews) - H. Lundbeck A/S (HLBBF) announced headline results from the Phase IV THRIVE trial evaluating eptinezumab, an investigational humanised monoclonal antibody administered intravenously, in adults with migraine who had an inadequate response to one prior CGRP-targeting pr
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.